Analysts Update Ratings for Kidney Care Provider DaVita

Wall Street Zen upgrades DaVita stock to 'buy' rating

Feb. 23, 2026 at 1:26pm

Got story updates? Submit your updates here. ›

A number of financial firms have recently modified their ratings and price targets on shares of DaVita Inc. (NYSE: DVA), a leading provider of kidney care services and dialysis treatments. The company, headquartered in Denver, Colorado, specializes in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease.

Why it matters

DaVita is a major player in the kidney care industry, operating over 2,800 dialysis clinics across the United States. Analyst ratings and price target changes can significantly impact investor sentiment and the company's stock price, which is closely watched by the healthcare investment community.

The details

On February 21, 2026, Wall Street Zen analysts upgraded their rating on DaVita from 'hold' to 'buy'. The analysts cited the company's strong market position, diversified service offerings, and potential for continued growth in the chronic kidney disease treatment market.

  • The analyst ratings updates occurred on February 21, 2026.

The players

DaVita Inc.

A leading provider of kidney care services and dialysis treatments, headquartered in Denver, Colorado.

Wall Street Zen

A financial analysis firm that recently upgraded its rating on DaVita stock.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

The takeaway

The positive analyst rating on DaVita's stock reflects the company's strong market position and growth potential in the kidney care industry, which continues to see rising demand for dialysis and other renal treatment services.